COMUNICADO: Tratamiento del cáncer hepático primario: El estudio SARAH completa el reclutamiento (y 2)

1) SorAfenib versus Radioembolization in Advanced Hepatocellular carcinoma
(SARAH): http://clinicaltrials.gov/ct2/show/NCT01482442.
2) Vilgrain V, Abdel-Rehim M, Sibert A et al. Radioembolisation with yttrium-90
microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma
(SARAH): study protocol for a randomised controlled trial. Trials 2014; 15: 474.
3) Llovet J, Ricci S, Mazzaferro V et al for the SHARP Investigators Study
Group. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine
2008; 359: 378-390.
4) Sangro B, Carpanese L, Cianni R et al on behalf of European Network on
Radioembolization with yttrium-90 resin microspheres (ENRY). Survival after 90Y resin
microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A
European evaluation. Hepatology 2011; 54: 868-878.
5) GLOBOCAN. Liver Cancer Incidence and Mortality Worldwide in 2012.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx accessed 10 February 2015.

Photo:
http://photos.prnewswire.com/prnh/20150304/732289-a

http://photos.prnewswire.com/prnh/20150304/732289-b

CONTACTO: Contactos: (En Francia) Marie-Hélène Coste Tel.:+33(0)1-44-61-13-46 e: costemh@gmail.com Press Service AP-HP Tel.:+33(0)1-40-27-37-22 e: service.presse@sap.aphp.fr (Fuera de Francia) IgaRawicka Tel.: +48-600-600-166 e: irawicka@sirtex-europe.com